Anumana

Anumana is a groundbreaking startup focusing on "Unlocking the Language of the Heart & Transforming Cardiac Through Cutting-Edge AI Solutions." Founded in 2021 and headquartered in the United States, Anumana is utilizing industry-leading AI and translational science to decode electrical signals from the heart more effectively than ever before. The company's goal is to empower healthcare providers to revolutionize patient care within the cardiac clinical pathway. With a recent acquisition of NeuTrace, Anumana is now leveraging the power of novel ECG-EGM-EMR integration for clinically valuable, actionable insights. The company combines unparalleled longitudinal structured and unstructured electronic medical record data with diagnostic and interventional ECGs and EGMs using nference’s proprietary nSights real-world evidence generation platform. Through the application of AI techniques to these electrical signals from the heart, Anumana has uncovered clinically critical electrical signatures and patterns unrecognizable to the human eye. The company has amassed an impressive track record with over 75+ peer-reviewed publications and ongoing research that demonstrates significant promise in the early detection and diagnosis of hidden conditions, leading to actionable insights for valuable patient interventions. This presents an opportunity to provide clinical decision support tools for each unique patient throughout the cardiac care continuum, paving the way for precision medicine. Anumana aspires to introduce a new standard of care in cardiac clinical care, supported by reimbursement. Anumana recently secured a significant $32.00M Venture Round investment on 17 November 2022, which signifies a strong vote of confidence in the company's mission and potential. With its focus on AI, Health Care, and Medical Devices, Anumana is positioned as an innovative player in the healthcare industry, poised to make a tangible impact in improving patient outcomes.